ADORA2B and neoplasm: Pharmacologic inhibition of Adora2b also restrained tumor growth in vivo; however, the effect of the small molecule inhibitor was not present in tumor growth in CD8KO mice indicating adenosine signaling through Adora2b significantly restrains CD8+ T cell anti-tumor activity in PDAC (4) (Figure 4, right panel).